EGFR and non-small cell lung carcinoma: With regards to EGFR TP53 comutations, there was a suggestive trend towards higher prevalence in women (42/69, 60.87% vs. 15/33, 45.45%, p= 0.2007; q= 0.2007) in HR+ NSCLC.